{"preliminary_commentary":{"by_channel":{"x_thread":151,"youtube":127,"podcast":50,"bluesky_thread":27,"x_video":7},"note":"Preliminary. Indexed podcasts, YouTube videos and X posts that name this trial so far. This is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this."},"free_build":{"available":true,"how":"POST https://www.erudio.com/api/trial-requests with {\"nct_id\": \"NCT03301220\", \"email\": \"<work email>\"}. The person who owns that inbox must confirm by the emailed link; agents cannot confirm. The result is the report's free public preview; the full report is still bought."},"commentary_summary":{"generated_at":"2026-10-29T04:46:54.443Z","note":"Automated from the 40 newest of 362 indexed sources (Apr 2026 – Oct 2026). Each question is raised in at least two. Not an Erudio report: no source links. Not medical advice.","passages_read":40,"text":"- Whether early treatment is appropriate or active monitoring remains reasonable\n- How high-risk smoldering myeloma should be defined\n- Whether early treatment improves outcomes beyond delaying progression\n- How daratumumab compares with more intensive early-treatment approaches"},"name":"AQUILA","nct_id":"NCT03301220","offer":{"currency":"USD","how":"Order at https://www.erudio.com/contact?report=aquila-nct03301220. The price is an estimate of verified statements from the commentary indexed so far, fixed at order. Final coverage is set when the report is built. We build the report within 24 hours of confirming the order and deliver it when it passes our checks; if it cannot be built to our standard, nothing is charged.","price_usd":1950,"size":"deep","size_rule":"Deep: 301+ verified statements, estimated at 14 per indexed commentary source"},"registry":{"acronym":null,"arms":[{"description":"Participants randomized to active monitoring will receive no study medication, but will undergo the same disease evaluations at the same frequency as participants randomized to daratumumab.","label":"Arm A: Active Monitoring","type":"NO_INTERVENTION"},{"description":"Participants will receive 1800 milligram (mg) of daratumumab co-formulated with 2000 units per milliliter (U/mL) of recombinant human hyaluronidase (rHuPH20) by subcutaneous (SC) injection until 39 cycles or up to 36 months or until confirmed disease progression, unacceptable toxicity or withdrawal from the study treatment, study termination or study completion.","label":"Arm B: Daratumumab SC","type":"EXPERIMENTAL"}],"collaborators":[],"completion_date":{"date":"2026-05-04","type":"ACTUAL"},"conditions":["Smoldering Multiple Myeloma"],"enrollment":{"count":390,"type":"ACTUAL"},"has_results":true,"interventions":[{"name":"Daratumumab SC: daratumumab + rHuPH20","otherNames":["JNJ-54767414"],"type":"DRUG"}],"last_update":"2026-06-08","lead_sponsor":"Janssen Research & Development, LLC","official_title":"A Phase 3 Randomized, Multicenter Study of Subcutaneous Daratumumab Versus Active Monitoring in Subjects With High-Risk Smoldering Multiple Myeloma","overall_status":"COMPLETED","phases":["PHASE3"],"primary_completion_date":{"date":"2024-05-01","type":"ACTUAL"},"primary_outcomes":[{"measure":"Progression-Free Survival (PFS) as Assessed by the Independent Review Committee (IRC)","timeFrame":"From randomization (Day -5) up to 77 months"}],"references":[{"citation":"Suzuki K, Kosugi H, Ito T, Takamatsu Y, Voorhees PM, Rajkumar SV, Ito M, Sakai C, Takahashi M, Nakatogawa T, Dennis R, Carson R, Dimopoulos MA. Japanese subgroup analysis of AQUILA trial: daratumumab vs active monitoring in high-risk smoldering multiple myeloma. Jpn J Clin Oncol. 2026 Sep 16:hyag146. doi: 10.1093/jjco/hyag146. Online ahead of print.","pmid":"42747040","type":"DERIVED"},{"citation":"Dimopoulos MA, Voorhees PM, Schjesvold F, Cohen YC, Hungria V, Sandhu I, Lindsay J, Baker RI, Suzuki K, Kosugi H, Levin MD, Beksac M, Stockerl-Goldstein K, Oriol A, Mikala G, Garate G, Theunissen K, Spicka I, Mylin AK, Bringhen S, Uttervall K, Pula B, Medvedova E, Cowan AJ, Moreau P, Mateos MV, Goldschmidt H, Ahmadi T, Sha L, Cortoos A, Katz EG, Rousseau E, Li L, Dennis RM, Carson R, Rajkumar SV; AQUILA Investigators. Daratumumab or Active Monitoring for High-Risk Smoldering Multiple Myeloma. N Engl J Med. 2025 May 8;392(18):1777-1788. doi: 10.1056/NEJMoa2409029. Epub 2024 Dec 9.","pmid":"39652675","type":"DERIVED"}],"start_date":{"date":"2017-11-07","type":"ACTUAL"},"study_type":"INTERVENTIONAL","title":"A Study of Subcutaneous Daratumumab Versus Active Monitoring in Participants With High-Risk Smoldering Multiple Myeloma","url":"https://clinicaltrials.gov/study/NCT03301220"},"report":null,"schema_id":"erudio.trial_listing","schema_version":"3.0","state":"listed","state_text":"No report yet. It can be ordered.","url":"https://www.erudio.com/trials/aquila-nct03301220"}